PAREXEL Biopharmaceutical R&D Statistical Sourcebook 2015/2016
LONDON, July 31, 2018 /PRNewswire/ -- PAREXEL Biopharmaceutical R&D Statistical Sourcebook 2015/2016 is the leading resource for statistics, trends, and proprietary market intelligence and analyses on the biopharmaceutical industry.Supported by thousands of graphs, illustrations, and analyses, the Sourcebook provides the latest intelligence on every aspect of biopharmaceutical development – from product discovery, to R&D performance and productivity, to time-to-market trends. With real-world analysis and key contributions from leading consultancies and experts, the Sourcebook includes:
Download the full report: https://www.reportbuyer.com/product/3150511
New proprietary analysis on US clinical trial starts, segmented by therapeutic category, as well as overall active clinical trials
Emerging data on worldwide and company-specific R&D pipelines and product launch trends
New analysis on emerging trends in pharma and biotech licensing deals and other partnerships critical to industry's R&D pipeline
Drug approval statistics compiled from FDA, EMA, and other regulatory agencies
Drug approval statistics compiled from FDA, EMA, and other regulatory agencies
New global R&D spending trends and other international R&D data from key markets
International statistics on drug development output
And much more!
Plus, NEW in the 2015/2016 edition:
Spotlight analyses on emerging and re-emerging elements of industry's R&D pipeline, including immuno-oncology, antibiotics, and gene therapy
Assessments of several emerging industry controversies, including drug pricing, the wisdom of ultrarapid new drug reviews, and R&D "overcrowding" in some parts of the new drug pipeline
Analyses on the state, nature, and sustainability of industry's pipeline of R&D projects
Detailed profiles on the pipelines and emerging R&D models and structures used by leading pharma companies
Analyses focused on the drug and biopharma markets and development pipelines within emerging countries, including South Korea and China
Assessments of personalized medicine/companion diagnostics, biosimilars, orphan drugs, and other factors reshaping biopharma R&D today
PAREXEL Biopharmaceutical R&D Statistical Sourcebook 2015/2016 is a must-have resource for the drug development industry. It is invaluable to executives and managers working in the pharma and biotech industries. The Sourcebook puts real-world data sets at your fingertips for presentations, reports, business development efforts, strategic meetings, and critical decision-making analyses. The 2015/2016 edition is also offered in electronic format for individual users, small groups, business units, or company-wide access.
Please read these important technical specifications carefully:
An internet connection, user name, and password are required, and will be established during the ordering process.
Your individual purchase includes access to one computer. Once you access the eStats from a computer, you cannot view it on any other computer. If you would like to access the eStats from multiple computers, you will need to purchase additional copies.
The eStats is not available in PDF format.
Printing, copying, and pasting is not permitted.
The file cannot be emailed or shared.
The content of the book is not updated. You will be notified when the 2016 edition is available, which will require a new purchase.
Download the full report: https://www.reportbuyer.com/product/3150511
About Reportbuyer
Reportbuyer is a leading industry intelligence solution that provides all market research reports from top publishers
For more information:
Sarah Smith
Research Advisor at Reportbuyer.com
Email: [email protected]
Tel: +1 (718) 213 4904
Website: www.reportbuyer.com
SOURCE ReportBuyer
Share this article